ArticleFrontiers in pharmacology2025
Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic lymphoma kinase (ALK) inhibitor alectinib has demonstrated significant potential in treating non-small cell lung cancer (NSCLC); however, its adverse effects remain a notable challenge for healthcare professionals. This report examines the case of a 79-year-old female lung cancer patient who presented with persistent colic in the left abdomen 10 months after initiating alectinib treatment. Upon admission, abdominal computed tomography revealed mild thickening of the descending colon wall, accompanied by free gas and surrounding exudation, leading to a diagnosis of descending colon perforation. After excluding alternative causes of gastrointestinal perforation, the condition was attributed to a severe adverse reaction associated with alectinib. While alectinib has been reported to cause serious gastrointestinal perforations, the underlying mechanism remains unclear and warrants further clinical investigation. Clinicians should be vigilant in recognizing and promptly managing this potential complication during alectinib therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.